Bonan Li
Changsha, 410208, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Investigating the potential active components and mechanisms of Xiongcan Yishen formula in treating late-onset hypogonadism using network pharmacology combined with metabolomics and absorbed components.
Journal: Journal of ethnopharmacology
Published: March 31, 2026
From "Passive Supplementation" to "Active Repair": Melatonin Reshapes the Treatment Paradigm for Late-Onset Hypogonadism by Targeting Leydig Cell Senescence.
Journal: Aging cell
Published: November 12, 2025
Bibliometric analysis of glycolysis and prostate cancer research from 2004 to 2024.
Journal: Discover oncology
Published: August 20, 2024
Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: January 23, 2024
Icariin‑curcumol promotes ferroptosis in prostate cancer cells through Nrf2/HO‑1 signaling.
Journal: Experimental and therapeutic medicine
Published: June 12, 2023
Icariin-Curcumol promotes docetaxel sensitivity in prostate cancer through modulation of the PI3K-Akt signaling pathway and the Warburg effect.
Journal: Cancer cell international
Published: April 14, 2023
Guilu-Erxian-Glue alleviates Tripterygium wilfordii polyglycoside-induced oligoasthenospermia in rats by resisting ferroptosis via the Keap1/Nrf2/GPX4 signaling pathway.
Journal: Pharmaceutical biology
Published: January 23, 2023
Effects of icariin and curcumol on autophagy, ferroptosis, and lipid metabolism based on miR-7/m-TOR/SREBP1 pathway on prostate cancer.
Journal: BioFactors (Oxford, England)
Published: October 26, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026